Outcomes of bone marrow mononuclear cell transplantation combined with interventional education for autism spectrum...

Area of Science:

• Regenerative Medicine
• Neurodevelopmental Disorders
• Clinical Trials

Background:

• Autism spectrum disorder (ASD) presents significant challenges in social communication and behavior.
• Existing interventions for ASD have varying degrees of efficacy, necessitating novel therapeutic approaches.
• Autologous bone marrow mononuclear cells (BM-MNCs) offer potential regenerative properties.

Purpose of the Study:

• To evaluate the safety and efficacy of autologous bone marrow mononuclear cell transplantation combined with educational intervention for children with autism spectrum disorder.
• To assess the impact of this combined therapy on ASD severity and adaptive behaviors.

Main Methods:

• An open-label clinical trial involving 30 children diagnosed with ASD.
• Autologous bone marrow was harvested, mononuclear cells isolated, and infused intrathecally twice, 6 months apart.
• Patients received 8 weeks of Early Start Denver Model educational intervention post-transplantation.

Main Results:

• No severe adverse events were reported, indicating a safe treatment profile.
• Significant reduction in autism severity, evidenced by a decrease in Childhood Autism Rating Scale (CARS) scores (P < .05).
• Marked improvements in adaptive capacity (Vineland Adaptive Behavior Scales), social communication, language, and daily skills; reduction in repetitive behaviors and hyperactivity.

Conclusions:

• Autologous bone marrow mononuclear cell transplantation combined with behavioral intervention is a safe and well-tolerated treatment for children with ASD.
• The combined approach demonstrates significant efficacy in ameliorating core ASD symptoms and improving overall adaptive functioning.
• This therapeutic strategy holds promise for improving outcomes in children with autism spectrum disorder.